10X Genomics

Shares of 10x Genomics climbed to a 52-week high of $66.95, giving it a market capitalization of $8.71 billion. InvestingPro rates the stock as overvalued relative to its fair value, while the annual return was about 385.93 percent. In Q2 2026, 10x Genomics beat revenue and earnings forecasts but issued a muted outlook due to the transition to the new Atera platform. Analysts reacted mixedly: Stifel reiterated a buy rating, RBC assigned a “Sector Perform” rating, and Canaccord raised the price target to $60. » More on de.investing.com

Cathie Wood–led ARK ETFs reported trades on August 14, 2026: the largest sale was 10,951 shares of 10X Genomics worth about $636,800, part of an ongoing reduction of the position. At the same time ARK bought 45,010 shares of Perceptive Capital Solutions for roughly $522,566 and increased holdings in Cerus and Schrödinger. Shares of the 3iQ Solana Staking ETF were also added, and smaller sales of Twist Bioscience and Brera Holdings were made. Overall, the transactions reflect a strategic portfolio reshuffle. » More on de.investing.com

10x Genomics shares rose to a new 52-week high of $50.36 after gaining 307.97% year-to-date and delivering a total return of 256% over the past twelve months. For Q2 2026 the company reported revenue of $151.04 million and an adjusted loss per share of $0.14, both better than expected. Despite the results, the stock fell after the announcement due to a more cautious near-term outlook and the transition to the new Atera platform. Data from InvestingPro suggest the stock is trading above its fair value, which is relevant for investors considering entry. » More on de.investing.com